Biomarker Development to Improve Trials for Type 1 Diabetes
Conference Recording Jan 20, 2014
About the SpeakerMatthias von Herrath, M.D. serves as Director of the Center for Type 1 Diabetes Research in addition to being a full Professor in the Division of Developmental Immunology. Dr. von Herrath and his team study why the immune system sometimes attacks the body's own cells. They focus on type 1 diabetes, a disease caused by the immune system attacking the insulin-producing beta cells in the pancreas, and on diseases caused by viral infections. Their goal is to develop and evaluate new treatments and therapies for these conditions, in particular immune-based interventions.
AbstractImmunotherapy of type 1 diabetes and other autoimmune disorders faces significant hurdles, because therapeutic efficacy needs to be balanced with acceptable side effects. Since development of disease also exhibits heterogeneity depending on age, environmental and genetic factors, it would be desirable to rationally develop a suitable and practical set of biomarkers, that should be able to segregate responders from non-responders and ideally predict efficacy of immune-based intervention on an individual basis. We have developed panel of biomarkers that are specifically based on novel insight into the pathogenesis of T1D achieved as part of the nPOD (national pancreatic organ donor) consortium. This strategy, its implication and realization in future clinical trials and potential impact on individualized medicine will be discussed.
Comments | 0 ADD COMMENT
Orphan Drugs and Rare Diseases Global Congress 2017 USA
Sep 12 - Sep 14, 2017